SGMT
Sagimet Biosciences Inc. Series A Common StockNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$437.82M
P/E Ratio
—
EPS
$-1.35
Beta
3.64
52W High
$11.41
52W Low
$3.32
50-Day MA
$6.26
200-Day MA
$6.64
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Sagimet Biosciences Inc. Series A Common Stock
Sagimet Biosciences Inc. (SGMT) is a forward-looking biotechnology firm dedicated to pioneering treatments for metabolic diseases, with a particular focus on non-alcoholic steatohepatitis (NASH). The company is advancing its lead therapeutic candidate through multiple clinical trial stages, leveraging innovative mechanisms aimed at improving patient outcomes significantly. Supported by a seasoned management team and a strong intellectual property portfolio, Sagimet is well-positioned to meet the rising demand for effective therapies in the metabolic disease market, presenting a compelling investment opportunity for institutional investors in the evolving biotech landscape.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | — |
| Operating Margin | 0.00% |
| Return on Equity | -36.00% |
| Return on Assets | -24.00% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $3.14 |
| Price-to-Book | 4.27 |
| Price-to-Sales (TTM) | 52.50 |
| EV/Revenue | 0.276 |
| EV/EBITDA | -1.93 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $61.18M |
| Float | $59.14M |
| % Insiders | 3.50% |
| % Institutions | 21.93% |
Historical Volatility
HV 10-Day
51.08%
HV 20-Day
138.85%
HV 30-Day
122.14%
HV 60-Day
102.37%
HV Rank
80.6%
Volatility is currently contracting
Analyst Ratings
Consensus ($26.20 target)
1
Strong Buy8
Buy1
HoldMore HEALTHCARE Stocks
Data last updated: 5/25/2026